NASDAQ:NEOS Neos Therapeutics (NEOS) Stock Price, News & Analysis → “The Biggest Bubble of All Time” – Here’s What to Do. (From Chaikin Analytics) (Ad) Free NEOS Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range$1.06▼$1.1850-Day Range$0.77▼$1.1852-Week Range$0.45▼$1.68Volume15.01 million shsAverage Volume7.44 million shsMarket Capitalization$57.22 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get Neos Therapeutics alerts: Email Address Ad Stansberry ResearchMysterious Gold Leverage Just AnnouncedWorld's biggest multibillionaire investor group is buying THIS by the tons Most folks have completely missed the fact that there's one group of investors so powerful they're literally buying ONE THING by the tons… Stacking it in their locked vaults on pallets in record numbers.Find out what it is and see how you can get in with just a few dollars. About Neos Therapeutics Stock (NASDAQ:NEOS)Neos Therapeutics, Inc., a pharmaceutical company, develops, manufactures, and commercializes products for the treatment of attention deficit hyperactivity disorder (ADHD) using its drug delivery technology platform. Its products are extended-release (XR) medications in orally disintegrating tablets or liquid suspension dosage forms. The company manufactures and markets Adzenys XR-ODT amphetamine for the treatment of ADHD; Cotempla XR-ODT methylphenidate to treat ADHD; Adzenys ER amphetamine for the treatment of ADHD; and generic Tussionex, a hydrocodone and chlorpheniramine polistirex XR oral suspension for cough and upper respiratory symptoms of a cold. It also offers NT0502, a clinical-stage product candidate that has completed Phase I pilot pharmacokinetic trial for the treatment of neurological conditions associated with excessive salivation and drooling to reduce chronic sialorrhea in patients. The company was incorporated in 2009 and is headquartered in Grand Prairie, Texas.Read More Ad Stansberry ResearchMysterious Gold Leverage Just AnnouncedWorld's biggest multibillionaire investor group is buying THIS by the tons Most folks have completely missed the fact that there's one group of investors so powerful they're literally buying ONE THING by the tons… Stacking it in their locked vaults on pallets in record numbers.Find out what it is and see how you can get in with just a few dollars. NEOS Stock News HeadlinesApril 21, 2024 | finance.yahoo.comCara Therapeutics, Inc. (CARA)March 3, 2024 | afr.comAvenue Bank wins full APRA licence, bank guarantees in sightApril 25, 2024 | Chaikin Analytics (Ad)“The Biggest Bubble of All Time” – Here’s What to Do.Despite AI's incredible run-up in 2023, we're getting some conflicting messages. Analysts at JP Morgan warn that an "AI-driven bubble" could drag the entire stock market down. Folks at Morgan Stanley say AI hysteria is creating conditions like the dot-com collapse. Even AI leaders (the people who benefit the most!) are getting worried.February 9, 2024 | benzinga.comPresidio Partners 2007 GP, L.P.'s Net WorthDecember 14, 2023 | finance.yahoo.comUSAntibiotics Expands Leadership Team with Appointment of Steven Lutz to Vice President of Strategic AccountsSeptember 11, 2023 | finanznachrichten.deEledon Pharmaceuticals, Inc.: Eledon Pharmaceuticals Appoints Industry Veteran James Robinson to its Board of DirectorsJuly 10, 2023 | finanznachrichten.deAytu BioPharma, Inc.: Aytu BioPharma Announces Submission of Cotempla XR-ODT Manufacturing Site Transfer Prior Approval SupplementJuly 10, 2023 | finance.yahoo.comAytu BioPharma Announces Submission of Cotempla XR-ODT(R) Manufacturing Site Transfer Prior Approval SupplementApril 25, 2024 | Chaikin Analytics (Ad)“The Biggest Bubble of All Time” – Here’s What to Do.Despite AI's incredible run-up in 2023, we're getting some conflicting messages. Analysts at JP Morgan warn that an "AI-driven bubble" could drag the entire stock market down. Folks at Morgan Stanley say AI hysteria is creating conditions like the dot-com collapse. Even AI leaders (the people who benefit the most!) are getting worried.May 29, 2023 | finance.yahoo.comADHD Therapeutics Market Size Worth USD 19740 Million by 2030 at 7.80% CAGR – Report by Market Research Future (MRFR)May 12, 2023 | marketwatch.comOverview of Attention Deficit Hyperactivity Disorder (ADHD) Drugs Market Dynamics and Trends for 2023-2030April 28, 2023 | marketwatch.comGlobal ADHD Medication Market Analysis and Business Growth Outlook [2023-2030]April 11, 2023 | marketwatch.comAttention Deficit Hyperactivity Disorder (ADHD) Market by Product Type and Consumers-2030April 4, 2023 | marketwatch.comAttention Deficit Hyperactivity Disorder (ADHD) Market 2023 Size and Forecast to 2031April 3, 2023 | benzinga.comAttention Deficit Hyperactivity Disorder Market to Register a Steady CAGR of 4.40% Between 2023 – 2031 | Growth Plus ReportsMarch 30, 2023 | marketwatch.comADHD Medication Market 2023 Size and Growth Forecast to 2028March 27, 2023 | marketwatch.com2023 Attention Deficit Hyperactivity Disorder (ADHD) Market: Top Players Best Practices and Sales Forecast 2030March 24, 2023 | marketwatch.comADHD Medication Market Outlook and Forecast till 2030March 21, 2023 | marketwatch.comAttention Deficit Hyperactivity Disorder (ADHD) Market Insights and Forecast to 2028March 16, 2023 | marketwatch.comThis report on ADHD Medication market presents a timeline of technical development and discusses how it affects the market.March 14, 2023 | marketwatch.comADHD Medication Market Analysis, Share by 2028February 27, 2023 | marketwatch.comGlobal Methylphenidate Drug Market Research Covers, Future Trends and Opportunities, Past, Present Data, and Deep Analysis 2030 By VMReportsFebruary 19, 2023 | marketwatch.comChildren Attention Deficit and Hyperactivity Disorder Market 2023: Strategies for Expanding into New Markets across Regions 2029February 15, 2023 | marketwatch.comAttention Deficit Hyperactivity Disorder (ADHD) Market Growth, Business Overview and Forecast to 2028January 23, 2023 | afr.comAvenue Bank aims to free up cash for small businessJanuary 20, 2023 | finance.yahoo.comNykode Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare ConferenceJanuary 11, 2023 | marketwatch.comAttention Deficit Hyperactivity Disorder (ADHD) Market Size 2028 Size Estimation, New Investment Opportunities with Top Countries DataSee More Headlines Receive NEOS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Neos Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/09/2020Today4/25/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical Preparations Sub-IndustryN/A Current SymbolNASDAQ:NEOS CUSIPN/A CIK1467652 Webwww.neostx.com Phone972-408-1300FaxN/AEmployees213Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($0.34) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-16,900,000.00 Net Margins-38.35% Pretax MarginN/A Return on EquityN/A Return on Assets-28.46% Debt Debt-to-Equity RatioN/A Current Ratio0.66 Quick Ratio0.53 Sales & Book Value Annual Sales$64.65 million Price / Sales0.89 Cash FlowN/A Price / Cash FlowN/A Book Value($0.12) per share Price / Book-9.58Miscellaneous Outstanding Shares49,757,000Free FloatN/AMarket Cap$57.22 million OptionableOptionable Beta1.50 Elon Musk's Next MoveWondering when you'll finally be able to invest in SpaceX, StarLink, or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.Get This Free Report Key ExecutivesMr. Gerald W. McLaughlin (Age 53)CEO, Pres & Director Comp: $561.95kMr. Richard I. Eisenstadt (Age 63)CFO, Treasurer & Corp. Sec. Comp: $387.59kMs. Margaret CabanoVP of OperationsMr. John P. Limongelli (Age 51)Sr. VP, Gen. Counsel & Corp. Sec. Mr. Joe CalarcoChief Compliance OfficerMs. Sarah FosterVP of HRMr. Russ McMahenSr. VP of R&DMore ExecutivesKey CompetitorsKronos BioNASDAQ:KRONReneo PharmaceuticalsNASDAQ:RPHMSCYNEXISNASDAQ:SCYXGain TherapeuticsNASDAQ:GANXHomology MedicinesNASDAQ:FIXXView All Competitors NEOS Stock Analysis - Frequently Asked Questions How were Neos Therapeutics' earnings last quarter? Neos Therapeutics, Inc. (NASDAQ:NEOS) posted its quarterly earnings data on Monday, November, 9th. The company reported ($0.10) earnings per share for the quarter, missing analysts' consensus estimates of ($0.05) by $0.05. The business had revenue of $12.54 million for the quarter. What is Mark Tengler's approval rating as Neos Therapeutics' CEO? 10 employees have rated Neos Therapeutics Chief Executive Officer Mark Tengler on Glassdoor.com. Mark Tengler has an approval rating of 26% among the company's employees. This puts Mark Tengler in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of Neos Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Neos Therapeutics investors own include Verastem (VSTM), SCYNEXIS (SCYX), TherapeuticsMD (TXMD), TG Therapeutics (TGTX), AcelRx Pharmaceuticals (ACRX), Exelixis (EXEL), Rigel Pharmaceuticals (RIGL), Progenics Pharmaceuticals (PGNX), T2 Biosystems (TTOO) and Agile Therapeutics (AGRX). When did Neos Therapeutics IPO? Neos Therapeutics (NEOS) raised $60 million in an IPO on Thursday, July 23rd 2015. The company issued 4,000,000 shares at $14.00-$16.00 per share. UBS Investment Bank, BMO Capital Markets and RBC Capital Markets acted as the underwriters for the IPO and JMP Securities was co-manager. This page (NASDAQ:NEOS) was last updated on 4/25/2024 by MarketBeat.com Staff From Our PartnersThe Best AI Stock to Own in the World Today is Trading for Just $25Banyan Hill PublishingConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThe A.I. story nobody is telling you (Read ASAP)TradeSmithThis Apple-like Innovator is Revolutionizing HealthcareWall Street StarHe Is Giving Away BitcoinCrypto Swap Profits“The Biggest Bubble of All Time” – Here’s What to Do.Chaikin AnalyticsYour Money is Not SafeAmerican Alternativetop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders Agency Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Neos Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
